Syndax Pharmaceuticals Inc 8-K Filing
Ticker: SNDX · Form: 8-K · Filed: Dec 19, 2025 · CIK: 1395937
| Field | Detail |
|---|---|
| Company | Syndax Pharmaceuticals Inc (SNDX) |
| Form Type | 8-K |
| Filed Date | Dec 19, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Syndax Pharmaceuticals Inc (ticker: SNDX) to the SEC on Dec 19, 2025.
How long is this filing?
Syndax Pharmaceuticals Inc's 8-K filing is 2 pages with approximately 528 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 528 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2025-12-19 16:30:26
Filing Documents
- sndx-20251218.htm (8-K) — 46KB
- sndx-ex3_1.htm (EX-3.1) — 248KB
- 0001193125-25-326961.txt ( ) — 430KB
- sndx-20251218.xsd (EX-101.SCH) — 25KB
- sndx-20251218_htm.xml (XML) — 5KB
03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On December 18, 2025, the Board of Directors of Syndax Pharmaceuticals Inc. (the " Company ") approved amendments to the Amended and Restated Bylaws (the " Bylaws ") of the Company, effective on such date. The amendments to the Bylaws provide that, beginning on December 18, 2025, shares of the Company's capital stock shall be issued solely in uncertificated form; however, shares represented by a certificate issued prior to December 18, 2025 shall remain in certificated form until such certificate is surrendered to the Company. The foregoing summary of the amendments effective December 18, 2025 does not purport to be complete and is qualified in its entirety by reference to the complete text of the Amended and Restated Bylaws of the Company, which are filed as Exhibit 3.1 hereto and are incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 3.1 Amended and Restated Bylaws of Syndax Pharmaceuticals Inc. dated December 18, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SYNDAX PHARMACEUTICALS, INC. Date: December 19, 2025 By: /s/ Michael A. Metzger Michael A. Metzger Chief Executive Officer